Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.7% |
| 2 | Financials | 7.47% |
| 3 | Consumer Discretionary | 6.7% |
| 4 | Communication Services | 6.02% |
| 5 | Healthcare | 4.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
4101
Sonida Senior Living
SNDA
$1.88B
| $280K | ﹤0.01% |
8,575
+704
| +9% | +$20.9K |
|
4102
CALL
Deere & Co
DE
$167B
| $279K | ﹤0.01% |
600
| – | – |
|
4103
Paysign
PAYS
$723M
| $279K | ﹤0.01% |
54,131
+1,504
| +3% | +$8.11K |
|
4104
Invesco NASDAQ 100 ETF
QQQM
$103B
| $279K | ﹤0.01% |
1,102
-137,500
| -99% | -$34.7M |
|
|
COSO
4105
CoastalSouth Bancshares
COSO
$332M
| $278K | ﹤0.01% |
11,971
+5,392
| +82% | +$120K |
|
4106
Cardiff Oncology
CRDF
$77.1M
| $278K | ﹤0.01% |
98,863
+11,624
| +13% | +$27K |
|
4107
EverCommerce
EVCM
$1.76B
| $277K | ﹤0.01% |
22,854
+1,101
| +5% | +$11.7K |
|
|
IMSR
4108
Terrestrial Energy
IMSR
$615M
| $277K | ﹤0.01% |
+45,275
| New | +$605K |
|
4109
RGC Resources
RGCO
$225M
| $277K | ﹤0.01% |
12,985
+1,288
| +11% | +$28.1K |
|
|
VENU
4110
Venu Holding Corp
VENU
$116M
| $274K | ﹤0.01% |
+32,569
| New | +$361K |
|
|
BRAG
4111
Bragg Gaming Group
BRAG
$55.2M
| $273K | ﹤0.01% |
130,200
| – | – |
|
|
FIG
4112
PUT
Figma
FIG
$12.7B
| $273K | ﹤0.01% |
7,300
| – | – |
|
4113
Douglas Elliman
DOUG
$184M
| $273K | ﹤0.01% |
114,996
+11,833
| +11% | +$30.4K |
|
4114
FuelCell Energy
FCEL
$1.73B
| $271K | ﹤0.01% |
37,099
+37,097
| +1,854,850% | +$303K |
|
4115
Vanguard Morningstar Mega Cap Growth ETF
MGK
$33.7B
| $270K | ﹤0.01% |
3,275
+890
| +37% | +$73.1K |
|
|
AARD
4116
Aardvark Therapeutics
AARD
$144M
| $269K | ﹤0.01% |
20,516
-19,410
| -49% | -$242K |
|
4117
PIMCO Corporate & Income Opportunity Fund
PTY
$2.51B
| $269K | ﹤0.01% |
+20,850
| New | +$282K |
|
4118
Friedman Industries
FRD
$324M
| $268K | ﹤0.01% |
13,071
+1,119
| +9% | +$23K |
|
|
CBK
4119
Commercial Bancgroup
CBK
$485M
| $267K | ﹤0.01% |
+10,886
| New | +$267K |
|
4120
CALL
DexCom
DXCM
$34.3B
| $265K | ﹤0.01% |
4,000
| – | – |
|
4121
Accuray
ARAY
$33.4M
| $265K | ﹤0.01% |
321,258
+9,644
| +3% | +$12K |
|
4122
Baytex Energy
BTE
$3.05B
| $264K | ﹤0.01% |
81,854
+10,435
| +15% | +$29.1K |
|
|
BZAI
4123
Blaize Holdings
BZAI
$164M
| $263K | ﹤0.01% |
135,013
+21,475
| +19% | +$69.5K |
|
4124
iShares Russell 1000 Growth ETF
IWF
$128B
| $263K | ﹤0.01% |
2,224
-193,916
| -99% | -$23M |
|
|
ZEPP
4125
Zepp Health
ZEPP
$79.9M
| $263K | ﹤0.01% |
9,766
-4,281
| -30% | -$153K |
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $49.1B in Q4 2025, closing 641 positions and reducing 1,715 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 20% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.